Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The solvency profile exhibits a period of increased leverage centered in early 2023, followed by a stabilization phase and a secondary upward trend in debt ratios leading into early 2026.
- Debt Leverage Ratios
- The Debt to Equity, Debt to Capital, and Debt to Assets ratios demonstrate synchronized movements throughout the period. A significant peak occurred in April 2023, where the Debt to Equity ratio reached 0.75 and the Debt to Assets ratio climbed to 0.27. Following a correction in late 2023—where the Debt to Equity ratio returned to a baseline of 0.42—a steady increase is observed through March 2026, with the Debt to Equity ratio ending at 0.68 and the Debt to Assets ratio returning to 0.27.
- Financial Leverage
- Financial leverage remained relatively stable compared to the more volatile debt ratios, fluctuating within a range of 2.33 to 2.77. The peak coincided with the leverage spike in April 2023. Subsequent to this peak, the ratio settled into a consistent range between 2.43 and 2.54, concluding at 2.47 in March 2026.
- Interest Coverage
- A substantial downward trend is evident in the interest coverage ratio, reflecting a decrease in the margin of safety for debt servicing. From a high of 164.15 in April 2022, the ratio declined precipitously to 19.09 by October 2023. Throughout 2024 and 2025, the ratio stabilized, fluctuating between a low of 23.10 and a high of 36.24, before closing at 25.00 in March 2026. While the coverage remains robust, the capacity to service interest from operating earnings has contracted significantly from initial levels.
Debt Ratios
Coverage Ratios
Debt to Equity
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Loans and notes payable | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Johnson & Johnson shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the organization exhibits periodic volatility in leverage levels, characterized by significant fluctuations in total debt against a backdrop of relatively stable shareholders' equity. The overall trend indicates a gradual increase in the dependency on debt financing toward the conclusion of the analyzed period.
- Total Debt Trends
- Debt levels experienced substantial volatility, peaking twice during the observed timeframe. An initial surge occurred in April 2023, reaching 52,907 million USD, followed by a sharp contraction to 29,332 million USD by December 2023. A second sustained increase began in March 2024, culminating in a period high of 54,987 million USD by March 2026.
- Shareholders' Equity Stability
- Equity remained comparatively stable, exhibiting a general upward trajectory. From a low of 68,774 million USD in December 2023, equity grew to 81,186 million USD by March 2026. This steady growth suggests a strengthening of the internal capital base, which provides a buffer against the periodic increases in total liabilities.
- Debt to Equity Ratio Analysis
- The debt to equity ratio mirrors the volatility of debt levels, fluctuating between a minimum of 0.42 in October 2023 and a maximum of 0.75 in April 2023. Following a period of deleveraging in late 2023, the ratio entered a rising phase, increasing from 0.43 in December 2023 to 0.68 by March 2026. This progression indicates a shifting capital structure with a higher proportion of debt relative to equity in the final quarters of the analysis.
Debt to Capital
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Loans and notes payable | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile reflects a period of significant volatility in debt levels, resulting in a fluctuating debt-to-capital ratio. While the ratio remained stable at approximately 0.30 during much of 2022 and late 2023, a general upward trend is observed toward the end of the analyzed period, reaching a peak of 0.40 by March 2026.
- Debt Accumulation and Volatility
- Total debt exhibited sharp fluctuations, characterized by two primary surges. The first peak occurred in April 2023, where debt rose to 52.9 billion USD. This was followed by a substantial reduction to 29.3 billion USD by December 2023. A second expansion phase began in late 2024, with debt climbing steadily from 36.6 billion USD in December 2024 to a period high of 54.9 billion USD by March 2026.
- Capital Base Dynamics
- Total capital remained relatively stable between 106 billion and 123 billion USD from 2022 through early 2023. A contraction occurred during the second half of 2023, reaching a low of 98.1 billion USD in December 2023. Subsequently, the capital base expanded, surpassing 130 billion USD in 2025 and reaching 136.1 billion USD by the conclusion of the period.
- Debt to Capital Ratio Interpretation
- The debt-to-capital ratio demonstrates a direct correlation with the observed debt spikes. The ratio peaked at 0.43 in April 2023, coinciding with the first major debt increase. After returning to a baseline of 0.30 in late 2023, the ratio climbed again, stabilizing between 0.37 and 0.40 from June 2024 through March 2026. This indicates an overall increase in financial leverage relative to the total capital structure over the long term.
Debt to Assets
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Loans and notes payable | |||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The analysis of the debt-to-assets ratio between April 2022 and March 2026 reveals a pattern of volatility in solvency metrics, with the ratio fluctuating between a low of 0.18 and a peak of 0.27. This indicates a periodic shift in the company's leverage strategy and capital structure over the observed timeframe.
- Leverage Trend Analysis
- The period began with a stable ratio of 0.18 to 0.19, which shifted upward to a peak of 0.27 by April 2023, corresponding with a rise in total debt to 52,907 million USD. A significant deleveraging phase followed, returning the ratio to 0.18 in the second half of 2023, as total debt decreased to approximately 29,332 million USD by December 2023.
- Recent Capitalization Patterns
- Starting in 2024, an upward trend in leverage re-emerged. The ratio climbed to 0.27 by March 2025, supported by a total debt increase to 52,252 million USD. Although a brief moderation to 0.24 occurred between June and December 2025, the period concluded with a return to 0.27 in March 2026, as total debt reached a period high of 54,987 million USD.
- Asset Base Correlation
- Total assets showed a general upward trajectory, growing from 178,355 million USD in April 2022 to 200,894 million USD by March 2026. The fluctuations in the debt-to-assets ratio appear to be primarily driven by volatility in total debt levels rather than significant contractions in the asset base, as total assets remained relatively resilient even during peaks in leverage.
Financial Leverage
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Johnson & Johnson shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of financial leverage from April 2022 through March 2026 reveals a period of moderate volatility followed by a phase of stabilization. The financial leverage ratio has fluctuated within a narrow range, primarily between 2.33 and 2.77, indicating a consistent approach to capital structure despite significant shifts in total assets and shareholders' equity.
- Asset Dynamics
- Total assets exhibited a fluctuating trajectory, beginning at 178,355 million USD in April 2022. A notable contraction occurred during the second half of 2023, reaching a period low of 166,061 million USD in October 2023. Following this decline, a consistent growth trend emerged, with assets expanding to exceed 200,000 million USD by March 2026.
- Equity Trends
- Shareholders' equity experienced a gradual decline from 74,709 million USD in early 2022 to a trough of 68,774 million USD by December 31, 2023. This downward movement reversed starting in 2024, characterized by a steady increase that peaked at 81,544 million USD in December 2025, before settling at 81,186 million USD by the end of the observed period.
- Financial Leverage Ratio Analysis
- The financial leverage ratio remained stable throughout 2022, hovering around 2.35. A significant spike occurred in April 2023, where the ratio peaked at 2.77, representing the highest level of leverage in the period. This increase suggests a temporary reduction in equity relative to total assets. Subsequent quarters showed a normalization process, with the ratio stabilizing between 2.43 and 2.54 from October 2023 through March 2026.
Overall, the relationship between asset growth and equity accumulation in the latter half of the period has resulted in a stabilized leverage profile. The convergence of assets and equity growth from 2024 onwards suggests a balanced expansion of the balance sheet, maintaining a leverage ratio that suggests a controlled reliance on debt to finance assets.
Interest Coverage
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||||
| Less: Net earnings (loss) from discontinued operations, net of tax | |||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||
| Add: Interest expense, net of portion capitalized | |||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Interest coverage
= (EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025)
÷ (Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of solvency metrics reveals a significant shift in the financial profile between the second quarter of 2022 and the first quarter of 2026, characterized by a substantial contraction in the interest coverage ratio and a marked increase in financing costs.
- Earnings Before Interest and Tax (EBIT) Performance
- EBIT exhibited considerable volatility over the analyzed period. Following a period of stability in early 2022, a sharp decline occurred in April 2023, where earnings reached a negative value of -1,075 million. A subsequent recovery was observed, culminating in a significant peak of 13,835 million in March 2025. For the remainder of the period through March 2026, earnings stabilized within a range of approximately 5,180 million to 7,738 million.
- Interest Expense Trends
- A pronounced upward trend in net interest expenses is evident. During the first three quarters of 2022, expenses remained relatively negligible, peaking at 51 million. Beginning in December 2022, these costs rose sharply to 177 million and remained consistently elevated, reaching a maximum of 308 million in June 2025. This trajectory indicates a significant increase in the cost of servicing debt or an expansion of total debt obligations.
- Interest Coverage Ratio Dynamics
- The interest coverage ratio experienced a severe compression. The period began with exceptionally high coverage, exceeding 140x throughout most of 2022. This ratio declined precipitously starting in late 2022, reaching a trough of 19.09 in October 2023. From 2024 through March 2026, the ratio entered a phase of relative stabilization, fluctuating between 23.00 and 36.24. Although these levels represent a significant decrease from the 2022 baseline, the ratio remains sufficiently high to suggest a comfortable margin for meeting interest obligations.